Broncus Closes Series C Financing

HONG KONG, Oct 14, 2020 - (ACN Newswire) - Broncus Holding Company ("Broncus"), a global leader in diagnostic and therapeutic technology for lung diseases, today announced the closing of a Series C round of funding led by Lake Bleu Capital, and including Baidu Capital, the venture arm of one of the world's largest Internet and data science companies, Ascendum Capital, CNCB Capital and DCP Capital, along with previous investor Qiming Venture Capital. The funds will be used to further develop markets and technology across lung cancer, emphysema and other important lung diseases. Efforts will include expanding global market adoption of the Archimedes Virtual Bronchoscopic Navigation System combining Fused Fluoroscopy, real-time bronchoscopy and virtual bronchoscopic navigation for 3D views and access to nodules anywhere in the lungs; expanded commercial adoption and global clinical studies of the InterVapor System for Bronchoscopic Thermal Vapor Ablation (BTVA) used in emphysema; U.S. and European studies of the EMPOWER RF Catheter used in Bronchoscopic Radiofrequency Ablation (BRFA); and further development of next-generation RF technology to precisely treat lung nodules.Zhan Guowei, CEO of Broncus, said, "In recent years, medical device leaders such as Medtronic and Johnson & Johnson have invested in the market development of technologies for lung disease, which validates our forward-looking vision to focus exclusively on the diagnosis and treatment of diseases in the lung. Securing investors such as Lake Bleu Capital, Baidu Capital and Intuitive Surgical further supports our strategy to 'own' the lung when it comes to diagnosis and treatment. Our breakthrough navigation technology is enabling us to accelerate the development and commercialization of precise interventional technologies for diagnosis and treatment in order to improve options for patients with lung diseases and the physicians that care for them."Dr. Li Bin, founder of Lake Bleu Capital, said: "Broncus is Lake Bleu's major investment in the medical device sector this year because they are addressing a large and unmet need globally in the diagnosis and treatment of lung diseases. Their world-leading Archimedes lung navigation technology is supported with robust data and uniquely helps physicians accurately locate and reach targeted lesions, which will open the door to new and exciting interventional lung therapies. We believe that Broncus is well positioned to lead the world in providing less invasive methods to diagnose and treat lung disease broadly."Broncus recently announced a new strategic partnership with Olympus Europa to exclusively distribute Broncus Medical's Archimedes Planner and Archimedes Lite Virtual Bronchoscopic Navigation (VBN) system in several European countries. Early investors in the company include Intuitive Surgical, an early pioneer and global technology leader in minimally invasive, robotic-assisted surgery.About Broncus Holding CompanyBroncus is dedicated to the development of diagnostic and therapeutic technology for lung disease. Founded in 2012, the company's primary technology platforms focus on the diagnosis of lung cancer and the treatment of emphysema. Its lung cancer portfolio includes the Archimedes System, Archimedes Planner, LungPoint Virtual Bronchoscopic Navigation (VBN) System, LungPoint Planner and FleXNeedle. The Archimedes System has been cleared by the FDA (U.S.), CE (Europe) and NMPA (China) and had broad patent protection globally. The InterVapor System has received the CE Mark.About Lake Bleu CapitalLake Bleu Capital is an investment platform that specializes in healthcare in Asia/Greater China. As one of the largest healthcare public equity funds in Asia, the USD public equity fund under Lake Bleu Capital has won multiple industry-leading performance awards for the region of Asia ex-Japan. Meanwhile, Lake Bleu Capital has also focused on private equity investments in the Chinese healthcare industry, successfully completing multiple investments in flagship innovative companies across different healthcare subsectors.Media Contact:BroncusShirley Deng Email: shirley.deng@dnamedtech.com Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Moonstake raises $1.04 Million – accelerating connection from staking to DeFi

SINGAPORE, Oct 14, 2020 - (ACN Newswire) - Moonstake today announced that it has successfully closed its seed round funding and has raised over $1.04 Million (approximately JPY 110 Million). Partnerships with more than 10 public blockchains such as Emurgo (one of Cardano's constituent corporations) and advanced products centered on staking wallets attracted a great deal of attention, leading to this procurement six months since it was founded. This procurement was carried out with Singapore-based venture capital firm Ruby Capital as the lead investor and financial investors with domestic and overseas bases as business partners.Since Moonstake was founded, Moonstake has sought to meet growing demand in Asia and globally by developing its own innovative staking protocols. Moonstake's product is a one-stop solution with staking capabilities that provides a gateway for users to facilitate their use of cryptocurrencies via web and mobile wallets (iOS/Android). Currently, Moonstake supports staking for ADA, Tezos, Cosmos, Ontology, QTUM, IRISnet, Harmon and further innovative products such as connection to DeFi via wallet will be developed in the future.With this funding, Moonstake will step up its existing staking pool operations and wallet service offerings. In addition, while further expanding the products and services for businesses that we have been promoting, we will build a platform for decentralized finance (DeFi), which we have been connecting for some time, and a protocol for solving staking liquidity. We will promote innovative initiatives in the DeFi area with development.Staking has been in full swing since 2019. Earlier this year, the market value of the staking market expanded 3.5 times in the 10 months from the beginning of the year, even in the single year of 2020, due to the PoS transition of well-known projects such as ADA and the start of staking.Against this backdrop, Moonstake has been developing more user-focused staking products to create Asia's largest staking pool network. The number of users continued to grow due to active alliances with public blockchains and marketing cooperation, and in October, Moonstake's total staking amounted to over $50Million.Panjun Wang, Partner at Ruby Capital says:Moonstake has continued delivering recorded achievements in the crypto staking service industry, and Ruby Capital is excited to be part of its journey from Staking to Defi. We look forward to the joint-developments and bringing more values to the users of the Moonstake!About MoonstakeMoonstake was recently established to develop a staking pool protocol to satisfy increasing demands in regional and global blockchain markets. Moonstake develops a staking pool protocol and provides business services through partners and companies.Moonstake aims to create the largest staking pool network in Asia, a robust environment for the cryptocurrency holders is one of its missions. Establishing a clear partnership roadmap with Moonstake represents another significant milestone for continuing to strengthen ties with leading platforms across Asia's burgeoning Distributed Ledger Technology (DLT) ecosystem. partnership has been announced with Emurgo, Ontology and NEO to boost staking adoption, Binarystar, Japan's biggest blockchain hub, OIO Holdings Limited (SGX: OIO), a Singapore Catalist-Listed company. Industry's reputed advisors, such as Lisk and Lawrence Lim of RAMP DEFI support Moonstake's innovative journey. https://www.moonstake.io/ About Ruby CapitalRuby Capital Pte Ltd., is a licensed venture capital fund manager regulated by the Monetary Authority of Singapore. The team employs industrial professionals and specialists in Singapore, Japan and China. Ruby partners with BinaryStar, Infinity Blockchain Group and others from China, Japan, South Korea, Singapore, and Europe with strong connections in Finance, IT Technology, Incubators, Education and Supply Chain industries. Ruby capital invests in artificial intelligence, data analytics, Fintech, consumer technology innovations, distributed ledger technologies (DLT), extended realities, quantum computing and other high-potential innovations. https://rubycapital.sg/ Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

天韵国际携多款自家品牌产品 精彩亮相2020年秋季全国糖酒会

HONG KONG, Oct 14, 2020 - (亚太商讯) - 中国领先的品牌加工水果产品销售商及制造商天韵国际控股有限公司(「天韵国际」及其附属公司统称「集团」,股份代号 : 6836.HK)欣然宣布,集团旗下全资附属山东天同食品有限公司(「天同食品」)及宜昌天同食品有限公司(「宜昌天同」)获邀参加于山东省济南市举办的2020年秋季全国糖酒会(「糖酒会」)。作为中国食品行业的「晴雨表」以及被业内人仕称为「天下第一会」,本届糖酒会吸引了近3,000家食品酒类企业参展,专业采购商多达15万人,是食品行业经销商采购产品的理想平台。集团于糖酒会的展览区域、产品展示以及经销商代表于展区与集团代表洽谈中于糖酒会上,集团凭借天然优质的产品以及多样化的包装形式,成功获得众多经销商的好评,重点展示了自家品牌「缤果时代」旗下的全新产品,连日来展销摊位人山人海,人流络绎不绝。是次参展有助促进集团与来自全国各地的经销商的直接沟通交流,为集团自家品牌销售的高速增长趋势奠定良好的基础。现时集团自家品牌产品销售覆盖全国27个省份、直辖市及自治区,品牌价值更首度跨越人民币15亿元大关。集团主席兼行政总裁杨自远先生表示:「我们很荣幸再次参与此业界的盛事,并获得一众经销商的青睐。我们将继续为消费者带来不同类别及水果品种的新产品,积极参与各类展览会,完善销售网络的布局,以拓展自家品牌产品地域覆盖范围,带来自家品牌销售强劲的增长动力。同时,通过多形式的线下和在线营销模式,加强与消费者互动,提升销售及在线线下自家品牌的形象,推动自家品牌业务的发展,巩固集团的市场领导地位。」关于天韵国际控股有限公司 (股份代号﹕6836.HK)天韵国际控股有限公司(「本公司」集团「统称(及其附属公司)」主要从事 (i) 生产及销售包装于金属罐、塑料杯,玻璃瓶及铝箔袋的加工水果产品及 (ii) 新鲜水果买卖。加工水果产品以自家品牌「缤果时代」、「果小懒」和「天同时代」及原厂委托制造代工方式出售。 集团致力于为客户提供健康安全的产品,作为国内外资质认证最为齐全的食品企业之一,时刻紧贴严格的国际生产标准,并就生产设施、质量监控及管理获授BRC(A)、IFS 食品(高级)、FDA(FSMA)、HALAL、 SC、KOSHER、BSCI 及ISO22000 等认证,集团还通过多个英国及美国超市内部的食品生产标准审核。 同时,集团作为中国「同线、同标、同质」工程出口食品企业,供应国内市场和供应国际市场的产品达到相同的质量水平。自2016 年起,集团自家品牌的优质加工水果产品继续获得市场的高度认可, 并获国家级机构颁授「中国罐头产品质量证明标志」的荣誉及资格,成为中国加工水果行业内能够在其产品贴上「零添加防腐剂」标志的首家水果加工商。 集团在2017 年分别被国际知名财经杂志《福布斯》评选为福布斯中国百强潜力上市公司及成为山东省临沂市荣获「2017 年度临沂市市长质量奖」荣誉的综合食品生产销售企业。集团全新自有研发及生产的纯水果休闲食品在2018 年也荣获中国国家知识产权局颁发「发明专利证书」。 集团及其「缤果时代」自家品牌于2019年分别被国家机构评为中国罐藏食品领先企业及领先品牌。欲了解更多集团详情,请浏览集团网站 www.tianyuninternational.com Copyright 2020 亚太商讯. All rights reserved. www.acnnewswire.com

Valarhash Introduces Mining Machine Hosting Plans and Services

CHENGDU, CHINA, Oct 14, 2020 - (ACN Newswire) - Valarhash, a one-stop digital asset service platform, has announced new mining machine hosting plans and services, internationally available since rolling out from the end of September. Valarhash aims to provide customers with one-stop mining services, competitive electricity plans, and professional mining support and maintenance operations, lowering the barriers of entry to mining. "At the moment, most of the available mining pool hosting sites are located in China," said Valarhash CEO Fiona Lv. "While based in Sichuan Province, our mining machine hosting services are available to international users who may choose to host their miners or join pools through any of Valarhash's 9 global data centers."The mining power capacities of the hosting service are 100MW in hydropower and 100MW in thermal power, while the mining machines supported include the Antminer S17 series, Whatsminer M20 series, Whatsminer M30 series, Antminer T19 series, and the highly sought after Antminer S19 series. A minimum of 100 hosting machines are available for this plan while the stock lasts. The GPU graphics machine is also available for mining Ethereum.The service provides customers with a steady source of electricity for mining, calculated seasonally with peak flood season electricity around 0.04 USD (0.25 RMB) per kWh and off-season prices around 0.05-0.06 USD (0.35-0.4 RMB) per kWh, or annually at around 0.05 USD (0.31 RMB) per kWh. Users may register at the Valarhash website and a representative will be in touch. Stability is at the forefront of Valarhash services. In a recent interview with Binance, Fiona Lv said that with greater stability, mining could yield long-term investment. Since mining operations began in July 2019, Valarhash has launched 1THash mining pool and products linked to 9% hash rate, 1TMine cloud mining platform, and mining farm management software Nelson, which enables users to track data clearly, and optimize investor returns. Please visit our official website or join us on social media:Website: https://www.valarhash.com/valarhash/indexTwitter: https://twitter.com/VaIarhashFacebook: https://www.facebook.com/ValarhashLinkedin: https://www.linkedin.com/company/vhash/Medium: https://medium.com/@ValarhashTelegram: https://t.me/valarhashx1tmineAbout ValarhashChengdu-based Valarhash integrates mining machine sales, miner hosting, and mining pool and mine construction services. Led by CEO Fiona Lv, Valarhash aims to provide users with transparent and beneficial mining plans using advanced technology, with a lower barrier of entry. Business operations cover hardware research and development, digital asset transactions and 1TMine hash power contract sharing. With a leading position in the hash power market, Valarhash integrates frontier resources with global vision, linking physical and digital worlds with blockchain technology. Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

华领医药宣布获得《药品生产许可证》

SHANGHAI, CHINA, Oct 14, 2020 - (亚太商讯) - 华领医药(「公司」,香港联交所主板股份代号:2552.HK)宣布,经过药品上市许可持有人(MAH) 体系审核和现场核查后,公司已获得由上海市药品监督管理局颁发的在研全球首创新药多扎格列艾汀(dorzagliatin)《药品生产许可证》。今年以来,华领医药成功完成两项 III 期新药上市注册临床试验的关键里程碑,其中包括在未用药 2 型糖尿病患者中开展的多扎格列艾汀单药治疗 III 期临床试验 SEED(HMM0301),和在二甲双胍足量治疗失效的 2 型糖尿病患者中开展的二甲双胍联合用药临床试验DAWN(HMM0302)。临床研究数据表明,在相应治疗周期内,多扎格列艾汀展现出了显著稳定疗效和安全性,并具有改善胰岛 β 细胞功能、促进胰岛素早相分泌和降低胰岛素抵抗的效果, 有望从根本上治疗糖尿病。8 月 17 日,华领医药与拜耳宣布建立战略合作,就多扎格列艾汀在中国达成商业合作协议。华领将负责产品的临床开发、生产供应、一级商分销、注册和药物警戒等工作;拜耳作为多扎格列艾汀中国独家推销商,负责其在中国的市场营销、推广和医学教育等活动,华领医药因此获得 3 亿元人民币首付款,还将获得最高 41.8 亿元的里程碑付款。获批《药品生产许可证》将进一步加速华领医药的新药上市申请(NDA)进程,为上市后药品的商业化生产供应做好了准备,并为未来产能的逐步提升打下了坚实的基础。根据新修订的《药品管理法》和《药品生产监督管理办法》,持有人作为从事药品生产的主体, 无论自行生产还是委托生产,都需取得《药品生产许可证》。华领医药是 2019 年 12 月 1 日新版《药品管理法》实施以来首批获得《药品生产许可证》的生物技术公司,取得《药品生产许可证》代表着华领医药和其委托生产的 CMO 已完成商业化生产准备的核心工作。华领医药在研全球首创新药多扎格列艾汀获批进入商业化阶段后,可以委托现有 CMO 公司进行药品生产,充分保证了上市后的药品供应。同时,《药品生产许可证》也是递交 NDA 的必要条件,将助力新药的获批进程。作为国内首批 MAH 制度试点企业,华领医药建立了一系列与持有人相匹配的、符合国际、国内标准的药物安全和药品质量管理体系。此次获得《药品生产许可证》,是对华领医药作为持有人管理能力和管理实践的进一步认可,意味着华领医药作为药品上市注册申请人和药品上市许可持有人,在药品生命周期质量管理、受托方生产管理、药物安全药物警戒管理、风险管理和产品上市后追溯体系和责任赔偿等方面完全具备持有人所必须的合规、高质量、高效率的管理体系和管理能力。华领医药 CEO 陈力博士表示:「获批《药品生产许可证》是华领医药的一项重要里程碑,是对华领医药一直以来所坚持的『高标准、高质量、创造高价值』准则的充分认可。华领将继续携手临床研究、药品生产和商业营销等领域的合作伙伴,让全球首创糖尿病新药多扎格列艾汀早日为广大患者带来福音。」关于 DorzagliatinDorzagliatin 是一款在研的全球首创双作用的葡萄糖激酶启动剂,旨在通过恢复 2 型糖尿病患者的血糖稳态来控制糖尿病渐进性退变性疾病发展。通过修复葡萄糖激酶的葡萄糖传感器功能的缺陷,dorzagliatin 具有恢复 2 型糖尿病患者受损的血糖稳态的潜力,可作为该疾病的一线治疗标准,或作为与目前批准的抗糖尿病药物联合使用的基础治疗。关于华领华领医药是一家立足中国,针对全球糖尿病患者尚未满足的临床需求,研发全球原创新药的生物技术公司。华领医药汇聚全球高端人才和科技资源,以国际领先生物医药投资团队为依托,成功将一款全球首创 2 型糖尿病口服新药推进到 NDA 申报准备阶段。目前,公司正在中国开展 2 个 III 期临床试验,同时在美国和中国进行多项早期临床试验,用以治疗成人 2 型糖尿病。其核心在研产品 dorzagliatin 已经达到单药治疗 III 期注册临床试验 24 周主要疗效终点, 并已完成整个 52 周试验。另一项与二甲双胍联合用药的 III 期注册临床试验也已达到 24 周主要疗效终点。公司已启动药品生命周期管理相关临床试验,并拓展糖尿病个性化治疗和管理的先进理念。通过与中国和全世界范围内的糖尿病领域专家和机构的密切合作,华领医药将为全世界糖尿病患者带来全新的治疗方案。详情垂询华领医药网址:www.huamedicine.com投资者电邮:ir@huamedicine.com媒体电邮:pr@huamedicine.com此新闻稿由博达浩华国际财经传讯公司代表华领医药发布。如有垂询,请联络︰博达浩华国际财经传讯公司李耀荣先生 +852 3150 6707 bunny.lee@pordahavas.com陈欣榆小姐 +86 75523807432 louisa.chen@pordahavas.com陈奕禧小姐 +852 3150 6733 cecilia.chen@pordahavas.com俞德怡小姐 +852 3150 6729 catherine.yu@pordahavas.com Copyright 2020 亚太商讯. All rights reserved. www.acnnewswire.com

Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin

SHANGHAI, CHINA, Oct 14, 2020 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.Since the beginning of this year, Hua Medicine has successfully completed two critical milestones for marketing registration, SEED (HMM0301), the Phase III clinical trial of dorzagliatin monotherapy in drug naive patients with Type 2 diabetes (T2D) and DAWN (HMM0302), the metformin combination clinical trial in T2D patients inadequately glycemic controlled with metformin. The results of the studies showed that, during the relevant treatment period, dorzagliatin has demonstrated its long-lasting efficacy and favorable safety profiles, and can improve the pancreatic beta-cell functions, promote early-phase insulin secretion and reduce insulin resistance, which is expected to fundamentally treat diabetes. On August 17, Hua Medicine and Bayer announced the establishment of their strategic partnership and concluded a cooperative agreement on the commercialization of dorzagliatin in China. Hua Medicine will be responsible for the clinical development, registration, product supply and distribution, whilst Bayer, as the exclusive promotion service provider for the product in China, will be responsible for its marketing, promotion and medical education activities in China. Hua Medicine will receive an upfront payment of RMB 300 million and additional payments could reach up to RMB 4.18 billion if certain milestones are met. The grant of the drug manufacturing permit will further accelerate the dorzagliatin New Drug Application (NDA) process of Hua Medicine, facilitate the commercial production and supply of the drug upon the product launch and lay a solid foundation for the expected increase of production capacity in the future.According to the newly revised Drug Administration Law and Administrative Measures for the Supervision and Administration of Drug Manufacturing, the MAH, as the main party engaged in drug manufacturing, must obtain the drug manufacturing permit, whether it manufactures drugs by itself or entrusts the manufacturing to a third party. Hua Medicine is among the first group of biotechnology companies that have obtained the drug manufacturing permit since the implementation of the new Drug Administration Law on December 1, 2019. The grant of the drug manufacturing permit indicates that Hua Medicine and its CMOs have completed the core work related to commercialization of the drug. After dorzagliatin is approved for commercialization, Hua Medicine may entrust the manufacturing of dorzagliatin to the current CMOs to prepare for product launch. At the same time, the drug manufacturing permit is a requisite for submitting the NDA, which will help speed up the approval process for new drugs.As one of the first batch of MAH enterprises in China, Hua Medicine has established management systems for drug safety/pharmacovigilance and pharmaceutical quality that are in line with its responsibilities as a MAH and also comply with international and domestic standards. The drug manufacturing permit granted for dorzagliatin is a recognition of Hua Medicine's management capabilities and management practices. It also means that Hua Medicine, who will become a drug marketing and registration applicant and a drug marketing license holder, fully possesses the compliant, high-quality and efficient management systems and management capabilities necessary for drug life-cycle quality management, entrusted production management, drug safety and pharmacovigilance management, risk management, post-market traceability system and liability compensation."The drug manufacturing permit granted for dorzagliatin marks an important milestone of Hua Medicine. It is also a full recognition of the principle of 'high standards and high quality to create high value' that Hua Medicine has always adhered to. Hua Medicine will continue to work with partners in the fields of clinical trial, drug production and commercialization to bring dorzagliatin, the first-in-class drug for diabetes, to patients in the world as soon as possible," said Dr. Li CHEN, CEO of Hua Medicine. About DorzagliatinDorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.About Hua MedicineHua Medicine is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its primary endpoint in both of its Phase III monotherapy and combination trials in China over the 24-week trial period, and completed its 52-week Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.comIssued by Porda Havas International Finance Communications Group for and on behalf of Hua Medicine. For further information, please contact:Mr. Bunny Lee +852 3150 6707 bunny.lee@pordahavas.com Ms. Louisa Chen +86 75523807432 louisa.chen@pordahavas.com Ms. Cecilia Chen +852 3150 6733 cecilia.chen@pordahavas.com Ms. Catherine Yu +852 3150 6729 catherine.yu@pordahavas.com Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

索尼国际教育携手网龙华渔教育推出 “教育云平台” 进军日本市场

HONG KONG, Oct 13, 2020 - (亚太商讯) - 全球领先的互联网社区创建者 - 网龙网络控股有限公司 (“网龙”或“本公司”,香港交易所股票代码:777)欣然宣布,网龙旗下教育业务子公司 - 网龙华渔教育与全球知名的索尼集团旗下教育子公司索尼国际教育于10月13日举办的第三届数字中国建设峰会数字丝路分论坛上共同发布了“教育云平台”产品,该平台将于10月在日本关东地区的重要县市开始逐步推行,为当地院校提供教育信息管理和教育大数据等服务。此次上线的“教育云平台”,是2019年9月双方签署“日本智慧教育云平台合作协议”后的首个落地项目,中日两国的教育资源也因此得到了进一步互利共通。为配合日本各地区迅速引入教育信息化解决方案,为学校提供优质教学管理工具,保证教学工作的正常开展,网龙近年在日本积极进行教育信息化布局,利用AI、互联网和大数据等技术,帮助当地解决教学信息管理问题,有效提升当地教育质量。此次与索尼国际教育共同合作发布的“教育云平台”,是基于网龙的SaaS服务平台并进行优化的产品。该平台利用“标准化+服务化+组件化”的方式提供教、学、练、测、评、推荐等核心教学活动,打造符合日本当地教育特色的综合管理服务平台。同时,该平台还将提供统一数据、统一接口规范、统一应用管理等功能,方便整合各种第三方能力和第三方资源,全面实现校园数字信息化,并运用大数据分析,提升学校管理信息化和决策科学化水平。该平台未来将进一步通过索尼国际教育的渠道向日本其他地区推广,并通过提供平台运营服务以及增值内容和服务进行变现。针对“教育云平台”的启动,索尼国际教育董事长兼CEO礒津政明表示:“与网龙华渔教育共同合作的‘教育云平台’具备强大的教育管理和大数据分析能力,可以很好地匹配个性化学习服务,并能进行可视化和多模块的灵活组装,同时操作简洁,系统稳定,是学校管理者及教师的得力助手。‘教育云平台’对未来的教育信息化发展起到了积极推动作用,未来将在日本更多地区进行推广与合作。”网龙CEO熊立博士表示:“对教育的不断探索、推出被行业认可的产品,是网龙始终坚持的初心。近年来,网龙通过技术输出、教育资源输出等手段,先后与多个国家建立合作关系,推动周边国家的教育科技发展,对世界输出了数字教育解决方案。凭借此次‘教育云平台’的落地,及合作伙伴索尼国际教育在日本市场的强大品牌、资源和渠道优势,网龙教育业务也期待为日本市场提供更多的增值服务,网龙更希望复制该模式,继续出海惠及全球。”关于网龙网络控股有限公司 网龙网络控股有限公司(香港交易所股份代号:777)是全球领先的互联网社区创建者,在开发和扩展多个互联网及移动平台方面拥有悠久的优良往绩,覆盖用户数以亿计,包括建立中国首个网络游戏门户–17173.com及打造最具影响力的智能手机服务平台–91无线。网龙于2020年7月27日正式获纳入恒生科技指数。 网龙成立于1999 年,成功自主研发多个著名的旗舰游戏,包括《魔域》、《征服》和《英魂之刃》,是中国最具声誉及知名度的网络游戏开发商之一。此外,网龙近年积极扩展在线教育业务,管理层秉承“打造全球最大的在线学习社区”的愿景,旨在将“未来教室”普及至世界各地的学校。更多资讯请访问 www.netdragon.com。关于索尼国际教育 索尼国际教育是索尼集团全资子公司,成立于2015年,秉承“教育,创造未来300年”的发展理念,以“让人人都能轻松便捷地享受教育;能与任何人互相学习和竞争;打破现有应用软件和服务的产品格局,创新教育基础平台”为己任,致力于提供跨越国界的、超越文化背景以及年龄差异的教育服务。索尼国际教育与世界各国的企业、教育相关团体、学校和教育培训机构等合作,创建全新的教育服务和平台,致力于推广普及STEM的理念,并提供优质的内容、服务以及探索新的教育方式。如有投资者垂询,敬请联络:网龙网络控股有限公司周鹰女士投资者关系高级总监电话:+852 2850 7266 / +86 591 8390 2825电邮:maggiezhou@nd.com.cn网站:ir.netdragon.com Copyright 2020 亚太商讯. All rights reserved. www.acnnewswire.com

WARC releases Guide to Brand activism in the Black Lives Matter era

LONDON, Oct 13, 2020 - (ACN Newswire) - The Black Lives Matter movement has galvanized consumers and employees, demanding brands to identify and double-down on how they respond to racial injustice. Brands now look to move forward effectively in a way that provides empathy, earnestness and empowerment in their engagement with Black communities.WARC Guide to Brand activism in the Black Lives Matter eraConsumers engagement with brands chartTo help marketers navigate these challenges and lead with purpose, WARC, the global authority on marketing effectiveness, has today released the WARC Guide to Brand activism in the Black Lives Matter era, compiling insights and learnings from prominent Black voices in the marketing community.Guest editor Kai D. Wright, Columbia University Lecturer, Ogilvy Global Consulting Partner, Author and Founder of blacklist 100, comments: "From the streets to boardrooms, Black Lives Matter has unified consumers and employees in fighting racial inequity, demanding more accountability from CEOs, organizations, and brands themselves."In the next 30 years, 90% of the US population growth will come from minority audiences, including Black households. This Guide offers research, inspiration, and advice on how to exercise brand accountability. Ultimately, it is a quick-start foundation for ethically activating Black Lives Matter to be relevant among, and resonate with, diverse communities by creating a new growth imperative based on their empowerment." Cathy Taylor, US Commissioning Editor, WARC, says: "Research shows consumers are demanding brands respond in ways that go beyond donations. This is not just about changing messaging or momentary gestures, it is about the very core of the business -- addressing challenges and taking the right steps to drive long term positive change. "We are delighted to have worked with guest editor Kai and our many esteemed contributors in our quest to help businesses respond in authentic and meaningful ways to the BLM movement." Providing guidance for advertisers, agencies and media owners, the report features case studies from brands who've done it well - including, Procter & Gamble, Ford and Netflix - data on changing attitudes around Black Lives Matter, what consumers want brands to do, the internal work that brands have to do towards diversity, equity and inclusion, and how that affects marketing outcomes.The eight key takeaways highlighted in WARC's Guide to Brand activism in the Black Lives Matter era are:1. The US is moving toward a majority-minority culture According to US Census data, in 2014 minorities made up 38% of the country, but by 2060 they will be in the majority at 56%. Marketers should no longer default to white culture. Non-US marketers should note the call for better representation is present in many markets, and lessons from the next wave of brand activism will be relevant globally.2. Black Lives Matter is bigger than messaging, affecting how brands operate internally and externally It is not just a multicultural issue; it's a human rights issue. And it's not just about posting a black square in protest on Instagram. For some brands, confronting racial injustice is new territory, but other brands came prepared. What they share is a strong brand purpose and often a history of addressing social issues.3. Addressing racial injustice is a business imperativeMore than a third of consumers have taken action based on a brand's approach to combating racial injustice - and they influence others to act in the same way. Especially in younger demographics, people say they will vote with their wallets and voices in terms of what brands they purchase.4. Brands need to accept discomfort and be prepared for polarization in addressing racial inequitiesConsumers firmly want brands to show solidarity but are torn as to what pace or scale. According to PSB Insights, there is clear polarization around how brands are seen as "responding to the current conversations and protests around racial injustice".5. Ads that reflect diversity workA global analysis of over 11,000 ads on Kantar's Link platform showed ads are more likely to get viewers' attention and be remembered if they feature people from diverse backgrounds. They're more enjoyable and involving, and show sales benefits.6. A brand purpose, alone, is not enoughIt only works when brands show true commitment and willingness to change. Visa, Levi's and P&G are committing to diversity, equity, and inclusion (DEI). Visa is reviewing progress every quarter.7. Media budgeting is overwhelmingly skewed toward the general populationOnly 6% of all US media spend of the total $480bn per year is geared toward minority groups. Brands need to act on bringing more equity to media investment.8. Consumers prefer concrete actionConsumers prefer community investments and internal diversity, over donations. Research by WARC and Wunderman Thompson shows that of 1,006 adults surveyed in the US from Sept 3-9, 47% of Black/African American versus 32% of the general population want brands to change current internal practices and policies.A sample of the WARC Guide to Brand activism in the Black Lives Matter era is available to download from content.warc.com/brand-activism-in-the-black-lives-matter-era-sample-report.html. The full report is available to WARC subscribers.To complement the Guide, WARC will host two webinars: October 27 with Monique Nelson, Chair and CEO at UWG and Kai D. Wright entitled Marketing to Multicultural Consumers Now and in the Coming Majority-Minority; October 28 with Kantar entitled A Global look at Racial Representation in Advertising.Paul Coxhill, Managing Director, WARC & Lions Intelligence, added: "WARC is committed to help advance diversity and inclusion in our industry. This Guide, together with our other BLM initiatives, will help brands, agencies, as well as the next generation of marketers, address the challenges and take the right steps to drive long term positive change." In response to the Black Lives Matter movement, WARC has joined forces with Cannes Lions (www.lovethework.com/) and industry bodies to partner with the HBCU Business Deans Roundtable (www.hbcubusinessdeans.org/) in the US to support future Black marketers, as well as partnering with the Black Cultural Archives (blackculturalarchives.org/) in the UK to produce the video series Hidden Figures: A look at Black British Marketing & Design (released from Oct 15). More information on www.warc.com/reports/BlackLivesMatterAbout WARC- a global authority on marketing effectivenessWARC is part of Ascential: the path-to-purchase company that combines intelligence, data and insights to drive growth in the digital economy. We do this by delivering an integrated set of business-critical products in the key areas of product design, marketing and sales.For over 30 years WARC has been powering the marketing segment by providing rigorous and unbiased evidence, expertise and guidance to make marketers more effective. WARC services include 18,000+ case studies, 90,000+ best practice guides, research papers, special reports and advertising trend data, webinars, awards, events and advisory services; has 1,200+ client companies, 21,500+ active users in 100+ markets; collaborates with 50+ industry partners; has offices in the UK, US, China and Singapore.Contact:Amanda Benfell Head of PR & Press +44 20 7467 8125 amanda.benfell@warc.com Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

国庆业绩远超去年同期 同程艺龙多项数据显示下沉市场增长空间巨大

HONG KONG, Oct 12, 2020 - (亚太商讯) - “久在樊笼里,复得返自然”。中秋国庆8天长假激发起人们内心出游的热情,大城市、小城市、甚至农村的人们都行动起来,来一趟红红火火的国内游。黄金周以来,中国领先的在线旅行平台同程艺龙(00780-HK)多项业务连续创下历史新高。仅9月30日单日,同程艺龙国内大交通(含机票、火车票、车船票)出行人次单日突破410万。长假前7日,同程艺龙平台国内酒店的预订量接连突破历史新高,较去年同期相比,预订量增长达到43%;国内大交通出票量比去年同期增长27%,其中汽车票出票量同比增长超过100%。国内游迎来6.37亿人次,下沉市场功不可没2020年中秋国庆长假8日,国内游迎来6.37亿人次,国人出游的热情可见一斑。据文旅部统计,国庆黄金周八天假期,全国共接待国内游客6.37亿人次,实现国内旅游收入4665.6亿元,旅游行业可谓迎来真正意义上的“黄金周”。国庆黄金周期间,中国出行市场迎来强势复苏。同程艺龙数据显示,2020年9月30日,国内大交通(含机票、火车票、车船票)出行人次单日突破410万,总出行人次同比增长22%,创历史新高。国内市场的强劲复苏,得益于下沉旅行市场需求的爆发。同程艺龙数据显示,10月1日至10月7日,同程艺龙平台来自三线及以下城市的大交通出票量同比增长超过35%——显著高于整体增速。经过疫情,低线城市消费者开始习惯线上预订机票、火车票、车票、酒店、门票……小程序即买即走的特性,大大促进低线城市用户线上消费习惯的养成。在下沉市场,同程艺龙有着天然优势。首先,公司拥有庞大的下沉市场客户群。截止2020年二季度末,同程艺龙新注册用户中来自非一线城市比例已达85.9%。疫情期间,同程艺龙持续巩固中国在线旅游市场,特别是低线市场领导地位。公司紧抓低线城市疫情复苏及增长机会,推出针对低线城市用户的定制推荐及推广活动。二季度,约63.1%微信平台付费用户来自中国三线或以下城市,较去年同期61.5%有所增加。同时,低线城市售出的间夜同比上升约15%。其次,借助多元化且有效的流量优势,同程艺龙很容易俘获下沉市场更多受众,并满足该市场出行需求。自2020年8月以来,同程艺龙火车票、机票、汽车票三大交通业务板块,已全部接入微信搜一搜。用户在微信中搜索“机票”、“火车票”或“汽车票”,可直接查询并预订相关出行产品。为了更好服务低线城市用户出行“第一公里”的需求,同程艺龙加强与公交集团、汽车营运商合作,将服务从机票、火车票的主动脉,延伸到汽车票、船票等毛细血管,并通过技术推动旅游资源的全面数字化。2020年国庆期间,该平台汽车票出票量实现了高速增长,同比增长达100%。“国庆中秋八天假期,激发了更多用户的出行需求。”同程艺龙CEO马和平表示,“在即将到来的第四季度,低线城市旅行需求的爆发,将持续推动行业的强势复苏。同程艺龙将继续助力中国旅游产业的数字化新基建,通过技术手段促进旅游线上化服务创新。”下沉市场高速增长带动酒店业复苏随着黄金周国内旅游热度的持续升温,中国的国内酒店预订量也持续攀高。同程艺龙数据显示,2020年10月1日至10月7日,同程艺龙平台国内酒店的预订量接连突破历史新高,较去年同期相比,预订量增长达到43%。和旅游业复苏一样,业内人士普遍认为,下沉旅游市场的高速增长是此次国庆酒店业复苏的重要因素之一。根据同程艺龙数据显示,十一期间来自三线及以下城市的酒店预订量同比增长超55%,显示出强劲的增长势头。在国庆前四日,在酒店预订量增速最快的城市中,郑州、周口、新乡、信阳等城市的酒店预订量同比增长超100%;长春、赣州、哈尔滨、台州、兰州、湛江、柳州、贵阳、海口、苏州等城市的酒店预订量同比增长超50%。同程艺龙COO(首席运营官)王强表示:“酒店高增长战略是同程艺龙的重要战略之一,我们的愿景始终是希望通过大数据和科技能力,为用户提供更好的住宿服务,并与产业链一起深挖住宿行业的机会,帮助合作伙伴提升服务和管理水平。”针对下沉市场,同程艺龙通过“扫码住”、“智慧酒店”等产品和服务,加速推动低线城市酒店预订的数字化进程,并通过提供全场景服务帮助用户更好完成酒店预订与入住。对低线城市的不断深耕,让同程艺龙在下沉市场的渗透率在行业保持领先。“一站式”智慧出行平台,或将先于同业复苏同程艺龙是中国在线旅行行业的创新者和领先者,由同程集团旗下同程网络与艺龙旅行网于2018年3月合并而成。2018年11月26日,同程艺龙成功在香港联交所主板挂牌上市。同程艺龙业务涵盖交通票务预订(机票、火车票、汽车票、船票等)、在线住宿预订、景点门票预订,及多个出行场景的增值服务,用户规模超过2亿,是中国两大出行平台之一。自新型冠状病毒疫情受控以来,中国内地恢复经济活动及生活秩序,与2020年第一季度显著下降相比,同程艺龙第二季度业绩呈复苏趋势。二季度公司收入约为12亿元,环比第一季度增加19.4%。得益于灵活的营运策略、严格的成本管控,以及轻资产营运模式,公司二季度经调整溢利净额约为1.96亿元,净利润率16.3%,远超市场预期。二季度平均月活跃用户、平均月付费用户分别恢复至1.76亿人次、1860万人次,环比一季度分别增加18.3%和25.7%。公司借助复苏趋势,持续优化品牌、产品及科技,灵活应对疫情下的国内旅游市场需求变化。2020年4月,同程艺龙推出全新的服务品牌“同程旅行”,启用新的品牌标识和品牌口号“再出发,就同程”,希望用更年轻的方式服务更多的用户。在业务推广方面,同程艺龙准备把握行业流量渠道变化机遇,除了现有依靠微信获得稳定流量来源外,公司还通过自有应用程序、轻应用程序以及不同平台直播等多种方式来拓展流量渠道。此外,公司还与华为、Vivo、Oppo等手机厂商及线下渠道合作,以具有效益的方式获取用户。经历疫情期间的积累蓄势,同程艺龙凭借较快复苏的下沉旅游市场、低获客成本、以及进一步提升营运效率,公司二季度表现优于同业平均值。背靠国内旅游市场复苏行情,同程艺龙复苏势头强劲,尤其是凭借其独有的下沉市场客群优势,公司恢复速度会较同业更快。 Copyright 2020 亚太商讯. All rights reserved. www.acnnewswire.com